{"success":true,"data":{"pressRelease":{"id":"130457","rtpr_id":"nGNX1mjB9V","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger","author":"Globe Newswire","published_at":"2026-08-28T14:07:56.098Z","article_body":"DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings\n(NASDAQ: NTHI), the most important part of the NEO100 story may no longer be\nwhether the company can produce a meaningful signal in recurrent brain cancer.\nAfter its latest Phase 2a readout, the bigger move is whether those results\ncan support a credible path toward registration.\n\nOn August 12, NeOnc reported positive topline results from the NEO100-01 Phase\n2a study in patients with recurrent or progressive Grade III and Grade IV\nIDH1-mutant glioma. The company reported 48.9% six-month progression-free\nsurvival, substantially above the prespecified 20% benchmark, with a reported\np-value of 0.0047. Median overall survival was reported at 26.09 months, while\n86.7% of patients were alive at six months. Five of the 24 patients remained\non treatment, including one patient with a partial response continuing beyond\n114 days.\n\nThose figures are still clinical-stage evidence, not proof of efficacy\nsufficient for approval, and the open-label Phase 2a design creates important\nlimitations. Yet, they represent a significant change in the information\navailable to investors. NeOnc now has a defined clinical dataset, survival\ninformation and, importantly, a specific regulatory objective: the company\nplans to request a Type B meeting with the FDA to discuss a potential\nregistrational pathway for NEO100.\n\nThat meeting could become the next major catalyst because it may help\ndetermine what the FDA would require to move the program forward. In other\nwords, the investment question could be shifting from “Does NEO100 work?”\nto “What would it take to get NEO100 to a potential approval?”\n\nThe science behind the program gives that question additional weight. NEO100\nis an intranasal formulation of purified perillyl alcohol being developed for\nCNS cancers. NeOnc's strategy is designed around delivering therapy through\nthe nasal route while addressing the challenges associated with treating\ntumors in the brain. The company is also developing NEO212, which has\ncompleted Phase 1 and established a recommended Phase 2 dose of 610 mg.\n\nNeOnc had already described the August clinical readout as “one of the most\nimportant clinical milestones in NeOnc’s history.” The subsequent data\nprovide context for that statement, while the upcoming FDA interaction could\ndetermine whether the milestone becomes a foundation for the next stage of\ndevelopment.\n\nThere are other signals worth watching. In June, NeOnc announced UAE IND\napprovals for NEO100 and NEO212, covering adult and pediatric development\nprograms. The company said the NEO100 authorization encompasses three clinical\nprograms ranging from Phase 1 through Phase 2. Meanwhile, CEO Amir Heshmatpour\nhas continued reporting open-market purchases of NTHI shares, following\nearlier buying and more than $500,000 in previously disclosed purchases.\nDirector Thomas Chen, M.D., Ph.D. also reported purchasing 33,787 shares at\n$3.8477 on August 14 and another 2,472 shares at $4.0445 on August 17,\naccording to the provided SEC filing information.\n\nThat creates interesting market dynamics, but the fundamental catalyst remains\nthe company's ability to translate clinical results into regulatory progress\nand that is ultimately what makes the current setup different.\n\nNeOnc remains a clinical-stage biotechnology company, with substantial risks\ninvolving additional trials, regulatory review, financing, manufacturing,\ncompetition and eventual commercialization. Phase 2a results do not guarantee\na successful registrational study or FDA approval.\n\nHowever, NEO100 has now crossed an important threshold, by reporting that its\nprimary endpoint was achieved, six-month PFS substantially exceeded its\nprespecified benchmark, median overall survival reached 26.09 months, and\nmanagement is preparing to engage the FDA about a potential registrational\nstrategy.\n\nFor NTHI, the next headline may matter more than the last one. The clinical\nquestion produced a meaningful answer. Now the regulatory question takes\ncenter stage.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nThis is a paid editorial communication intended for informational purposes\nonly. 24/7 is compensated by NTHI to provide ongoing news coverage of expected\nupcoming catalysts and events as well as market outreach services. For further\ndisclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=AxVaDlACGX8egEJt5ao7vinx0ejID0_wz28qmG9jWUeawxwbPlPHHyBEdgbIicCNvX4uikO7hiwkODBy1Q-IBo7uIU_og0v-ePfgqG3-t6Y=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1mjB9V","title":"NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger","author":"Globe Newswire","ticker":"NTHI","created":"2026-08-28T14:07:56.098Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings\n(NASDAQ: NTHI), the most important part of the NEO100 story may no longer be\nwhether the company can produce a meaningful signal in recurrent brain cancer.\nAfter its latest Phase 2a readout, the bigger move is whether those results\ncan support a credible path toward registration.\n\nOn August 12, NeOnc reported positive topline results from the NEO100-01 Phase\n2a study in patients with recurrent or progressive Grade III and Grade IV\nIDH1-mutant glioma. The company reported 48.9% six-month progression-free\nsurvival, substantially above the prespecified 20% benchmark, with a reported\np-value of 0.0047. Median overall survival was reported at 26.09 months, while\n86.7% of patients were alive at six months. Five of the 24 patients remained\non treatment, including one patient with a partial response continuing beyond\n114 days.\n\nThose figures are still clinical-stage evidence, not proof of efficacy\nsufficient for approval, and the open-label Phase 2a design creates important\nlimitations. Yet, they represent a significant change in the information\navailable to investors. NeOnc now has a defined clinical dataset, survival\ninformation and, importantly, a specific regulatory objective: the company\nplans to request a Type B meeting with the FDA to discuss a potential\nregistrational pathway for NEO100.\n\nThat meeting could become the next major catalyst because it may help\ndetermine what the FDA would require to move the program forward. In other\nwords, the investment question could be shifting from “Does NEO100 work?”\nto “What would it take to get NEO100 to a potential approval?”\n\nThe science behind the program gives that question additional weight. NEO100\nis an intranasal formulation of purified perillyl alcohol being developed for\nCNS cancers. NeOnc's strategy is designed around delivering therapy through\nthe nasal route while addressing the challenges associated with treating\ntumors in the brain. The company is also developing NEO212, which has\ncompleted Phase 1 and established a recommended Phase 2 dose of 610 mg.\n\nNeOnc had already described the August clinical readout as “one of the most\nimportant clinical milestones in NeOnc’s history.” The subsequent data\nprovide context for that statement, while the upcoming FDA interaction could\ndetermine whether the milestone becomes a foundation for the next stage of\ndevelopment.\n\nThere are other signals worth watching. In June, NeOnc announced UAE IND\napprovals for NEO100 and NEO212, covering adult and pediatric development\nprograms. The company said the NEO100 authorization encompasses three clinical\nprograms ranging from Phase 1 through Phase 2. Meanwhile, CEO Amir Heshmatpour\nhas continued reporting open-market purchases of NTHI shares, following\nearlier buying and more than $500,000 in previously disclosed purchases.\nDirector Thomas Chen, M.D., Ph.D. also reported purchasing 33,787 shares at\n$3.8477 on August 14 and another 2,472 shares at $4.0445 on August 17,\naccording to the provided SEC filing information.\n\nThat creates interesting market dynamics, but the fundamental catalyst remains\nthe company's ability to translate clinical results into regulatory progress\nand that is ultimately what makes the current setup different.\n\nNeOnc remains a clinical-stage biotechnology company, with substantial risks\ninvolving additional trials, regulatory review, financing, manufacturing,\ncompetition and eventual commercialization. Phase 2a results do not guarantee\na successful registrational study or FDA approval.\n\nHowever, NEO100 has now crossed an important threshold, by reporting that its\nprimary endpoint was achieved, six-month PFS substantially exceeded its\nprespecified benchmark, median overall survival reached 26.09 months, and\nmanagement is preparing to engage the FDA about a potential registrational\nstrategy.\n\nFor NTHI, the next headline may matter more than the last one. The clinical\nquestion produced a meaningful answer. Now the regulatory question takes\ncenter stage.\n\nAbout 24/7 Market News\n\nIn today's fast-moving markets, visibility is everything and 24/7 Market News\n(24/7) provides a powerful suite of investor relations and public relations\nsolutions designed to elevate your company’s profile quickly and\neffectively. Whether you're an established name seeking broader awareness, or\na micro-cap looking to break out of obscurity, 24/7 delivers targeted,\nhigh-impact coverage through timely news distribution, analyst report\nplacements, featured editorials, and multi-channel amplification across\nfinancial platforms, social media, and investor communities. Our services help\ncut through the noise, attract institutional interest, drive exposure, and\nbuild long-term shareholder credibility, all while maintaining full SEC\ncompliance and transparency. For Analyst Report coverage, custom IR campaigns,\npress release syndication, or other tailored investor and public relations\nsolutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate\nyour company’s visibility and valuation trajectory.\n\nThis is a paid editorial communication intended for informational purposes\nonly. 24/7 is compensated by NTHI to provide ongoing news coverage of expected\nupcoming catalysts and events as well as market outreach services. For further\ndisclosure information, please click here\n(https://www.globenewswire.com/Tracker?data=AxVaDlACGX8egEJt5ao7vinx0ejID0_wz28qmG9jWUeawxwbPlPHHyBEdgbIicCNvX4uikO7hiwkODBy1Q-IBo7uIU_og0v-ePfgqG3-t6Y=).\nThis should not be construed as financial or investment advice. Trading\ninvolves substantial risk; consult your financial advisor.\n\nImportant Editorial Note: 247 highlights companies approaching significant\ncatalysts and inflection points. This report reflects information available at\nthe time of publication. Since developments can occur rapidly, readers should\nindependently verify current information and review all company filings and\ndisclosures.\n\nCONTACT:\n24/7 Market News\nEditor@247mnn.com\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f91276c-d820-4666-8efc-2d8786490903)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-28T14:07:56.143726119Z","server_sent_at_ms":1787926076143},"received_at":"2026-08-28T14:07:56.203Z","source_url":null},"analysis":{"id":"119370","press_release_id":"130457","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Article is a paid editorial communication from 24/7 Market News, which is compensated by NTHI for coverage.","Phase 2a trial was open-label, introducing limitations to the efficacy conclusions."],"eventType":"clinical_trial","narrative":"NeOnc reported positive Phase 2a data for NEO100 in recurrent glioma, showing 48.9% six-month progression-free survival against a 20% benchmark with a p-value of 0.0047.\n\nMedian overall survival was 26.09 months, and the company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway.\n\nRecent insider activity includes purchases by CEO Amir Heshmatpour and Director Thomas Chen, who bought over 36,000 shares combined in mid-August.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Paid promotional content reporting positive Phase 2a data; treat as low signal."},"keyFigures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"p_value":0.0047,"total_patients":24,"median_os_months":26.09,"benchmark_percent":20,"patients_on_treatment":5,"six_month_pfs_percent":48.9,"six_month_survival_percent":86.7}},"quotedText":"one of the most important clinical milestones in NeOnc’s history","namedEntities":{"people":[{"name":"Amir Heshmatpour","role":"CEO"},{"name":"Thomas Chen","role":"Director"}],"products":["NEO100","NEO212"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI"},{"name":"24/7 Market News","relationship":"paid publisher"},{"name":"FDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"$500,000","context":"previously disclosed insider purchases"},{"amount":"$3.8477","context":"share purchase price by Director Thomas Chen"},{"amount":"$4.0445","context":"share purchase price by Director Thomas Chen"}]},"materialImpact":{"score":3,"reasoning":"Positive Phase 2a results for lead asset NEO100, hitting the primary endpoint with strong statistical significance and median OS of 26 months. The company plans a Type B FDA meeting to discuss registration. However, the data comes from an open-label trial and was released via a paid promotional editorial rather than a standard corporate filing, which impacts the immediate reliability of the signal."},"tickerRelevance":{"others":[],"primary":"NTHI"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["insider_transaction"],"importanceComponents":{"sourceType":"paid_promotion","tickerTier":"micro_cap","eventGravity":"clinical_readout_via_paid_pr"}},"event_type":"clinical_trial","event_type_secondary":["insider_transaction"],"sentiment":"bullish","material_impact_score":3,"narrative":"NeOnc reported positive Phase 2a data for NEO100 in recurrent glioma, showing 48.9% six-month progression-free survival against a 20% benchmark with a p-value of 0.0047.\n\nMedian overall survival was 26.09 months, and the company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway.\n\nRecent insider activity includes purchases by CEO Amir Heshmatpour and Director Thomas Chen, who bought over 36,000 shares combined in mid-August.","key_figures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"p_value":0.0047,"total_patients":24,"median_os_months":26.09,"benchmark_percent":20,"patients_on_treatment":5,"six_month_pfs_percent":48.9,"six_month_survival_percent":86.7}},"named_entities":{"people":[{"name":"Amir Heshmatpour","role":"CEO"},{"name":"Thomas Chen","role":"Director"}],"products":["NEO100","NEO212"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI"},{"name":"24/7 Market News","relationship":"paid publisher"},{"name":"FDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"$500,000","context":"previously disclosed insider purchases"},{"amount":"$3.8477","context":"share purchase price by Director Thomas Chen"},{"amount":"$4.0445","context":"share purchase price by Director Thomas Chen"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-28T14:13:21.793Z","global_importance":10,"audience_relevance":15,"importance_components":{"sourceType":"paid_promotion","tickerTier":"micro_cap","eventGravity":"clinical_readout_via_paid_pr"}},"durationMs":119555,"modelName":"glm-4.7"}}